Celldex Therapeutics
CLDX
30.43
-0.58
-1.85%
Celldex Therapeutics
US · CLDX
#2630 by market cap
Listed 1970
30.43
-0.58
-1.85%
Live - 5344 symbols - heartbeat 407s ago
· 2026-10-08 06:17
Pre-market
30.24
-0.63%
After-hours
30.51
+0.26%
- Market cap
- 2.39B
- P/E (TTM)i
- -7.00
- P/Bi
- 3.34
- EPSi
- -3.90
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on CLDX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 20.70, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -77.99% YoY
Margins
- Operating margin
- -18,599.81%
- Net margin
- -16,748.03%
Key ratios & quality
- Altman Z-Scorei
- 20.70
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.54M | 3.57M | 7.42M | 4.65M | 2.36M | 6.88M | 7.02M | 1.55M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 19.27M | 15.43M | 14.46M | 20.49M | 27.20M | 30.91M | 38.55M | 43.84M |
| Research & development | 66.45M | 42.67M | 42.53M | 53.31M | 82.26M | 118.01M | 163.55M | 245.07M |
| Operating profit | -76.40M | -54.53M | -49.57M | -69.15M | -107.10M | -142.04M | -195.08M | -287.37M |
| Pretax profit | -151.95M | -50.88M | -60.95M | -70.74M | -112.33M | -141.43M | -157.86M | -258.76M |
| Tax | -765.00K | 0 | -1.17M | -227.00K | -- | -- | -- | -- |
| Net profit | -151.18M | -50.88M | -59.78M | -70.51M | -112.33M | -141.43M | -157.86M | -258.76M |
| Basic EPS | -14 | -4 | -2 | -2 | -2 | -3 | -2 | -4 |
| Diluted EPS | -14.48 | -3.51 | -2.02 | -1.64 | -2.40 | -2.92 | -2.45 | -3.90 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 695.00K | 730.00K | 0 | 121.00K | 15.00K | 22.00K |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 10.82M | 10.39M | 10.69M | 11.94M | 11.45M | 13.10M |
| Research & development | 52.61M | 54.20M | 62.93M | 75.33M | 73.00M | 67.54M |
| Operating profit | -62.74M | -63.86M | -73.62M | -87.15M | -84.44M | -80.62M |
| Pretax profit | -53.80M | -56.60M | -67.04M | -81.32M | -78.69M | -73.50M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -53.80M | -56.60M | -67.04M | -81.32M | -78.69M | -73.50M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.81 | -0.85 | -1.01 | -1.22 | -1.18 | -0.94 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 99.08M | 66.70M | 197.84M | 410.84M | 317.69M | 431.69M | 747.16M | 534.66M |
| Cash & ST investments | 94.02M | 64.38M | 194.42M | 408.25M | 304.95M | 423.60M | 725.28M | 518.57M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 155.81M | 122.93M | 235.84M | 444.65M | 352.74M | 465.63M | 792.34M | 582.98M |
| Total current liabilities | 12.60M | 11.64M | 14.21M | 16.53M | 18.61M | 31.13M | 39.50M | 50.99M |
| Short-term debt | -- | 1.94M | 1.33M | 1.75M | 1.45M | 1.61M | 1.45M | 1.55M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 31,749,000.00 | 28,907,000.00 | 26,481,000.00 | 25,178,000.00 | 26,531,000.00 | 36,456,000.00 | 45,335,000.00 | 55,818,000.00 |
| Total equity | 124.06M | 94.03M | 209.36M | 419.48M | 326.20M | 429.17M | 747.01M | 527.17M |
| Retained earnings | -962.44M | -1.01B | -1.07B | -1.14B | -1.26B | -1.40B | -1.56B | -1.81B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 693.76M | 648.40M | 604.34M | 534.66M | 459.22M | 724.93M |
| Cash & ST investments | 673.29M | 630.34M | 583.22M | 518.57M | 451.46M | 717.59M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 739.47M | 692.41M | 648.44M | 582.98M | 511.25M | 782.35M |
| Total current liabilities | 32.02M | 32.96M | 46.47M | 50.99M | 51.47M | 61.33M |
| Short-term debt | 1.50M | 1.54M | 1.55M | 1.55M | 1.47M | 1.56M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 36,490,000.00 | 37,001,000.00 | 50,076,000.00 | 55,818,000.00 | 55,028,000.00 | 67,785,000.00 |
| Total equity | 702.98M | 655.41M | 598.36M | 527.17M | 456.23M | 714.56M |
| Retained earnings | -1.61B | -1.67B | -1.73B | -1.81B | -1.89B | -1.97B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -75.24M | -46.42M | -40.40M | -60.91M | -103.73M | -107.29M | -157.78M | -210.95M |
| Depreciation & amortization | 3.80M | 4.86M | 3.93M | 3.07M | 2.90M | 3.01M | 3.18M | 3.38M |
| Free cash flow | -76.05M | -47.15M | -41.96M | -62.16M | -105.56M | -109.11M | -159.70M | -213.66M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 29.02M | 16.25M | 170.79M | 269.89M | 0 | 216.22M | 432.30M | 0 |
| Ending cash balance | 24.31M | 11.23M | 43.84M | 39.14M | 29.43M | 34.81M | 28.36M | 28.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -54.37M | -44.01M | -48.63M | -63.94M | -65.59M | -57.41M |
| Depreciation & amortization | 867.00K | 873.00K | 824.00K | 816.00K | 854.00K | 902.00K |
| Free cash flow | -54.64M | -44.73M | -49.07M | -65.22M | -67.23M | -60.59M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 0 | 0 | 323.83M |
| Ending cash balance | 17.14M | 23.04M | 36.04M | 28.87M | 35.73M | 47.45M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -83.89 | -46.66 | -39.41 | -22.43 | -30.13 | -37.45 | -26.84 | -40.62 |
| ROA %i | -64.14 | -36.51 | -33.32 | -20.72 | -28.17 | -34.56 | -25.10 | -37.63 |
| ROIC %i | -83.89 | -45.14 | -38.50 | -22.20 | -29.84 | -37.12 | -26.70 | -40.42 |
| 5-year avg ROE %i | -52.48 | -52.92 | -50.66 | -45.89 | -44.50 | -35.21 | -31.25 | -31.49 |
| EBIT margin %i | -801.05 | -1,526.03 | -668.27 | -1,486.73 | -4,543.74 | -2,063.66 | -2,778.89 | -18,599.81 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.86 | 5.73 | 13.93 | 24.86 | 17.07 | 13.87 | 18.91 | 10.49 |
| Quick ratioi | 7.71 | 5.62 | 13.81 | 24.71 | 16.41 | 13.69 | 18.38 | 10.21 |
| Debt / assetsi | 0.00 | 2.97 | 1.48 | 0.68 | 1.14 | 0.55 | 0.48 | 0.40 |
| LT debt / equityi | -- | 1.82 | 1.03 | 0.31 | 0.79 | 0.22 | 0.32 | 0.15 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 20.29 | -19.25 | -16.50 | -21.29 | -12.95 | -2.46 | 14.71 | -13.13 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -23.20 | -27.18 | -32.44 | -40.62 | -48.94 | -43.88 |
| ROA %i | -22.24 | -25.96 | -30.52 | -37.63 | -45.36 | -40.76 |
| ROIC %i | -23.12 | -27.08 | -32.31 | -40.42 | -48.71 | -43.62 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -2,873.52 | -4,054.40 | -9,859.22 | -18,599.81 | -35,729.83 | -206,220.25 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 21.67 | 19.67 | 13.01 | 10.49 | 8.92 | 11.82 |
| Quick ratioi | 21.06 | 19.13 | 12.55 | 10.21 | 8.78 | 11.71 |
| Debt / assetsi | 0.46 | 0.44 | 0.40 | 0.40 | 0.37 | 0.63 |
| LT debt / equityi | 0.27 | 0.23 | 0.18 | 0.15 | 0.10 | 0.47 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development, manufacturing and commercialization of novel therapeutics for human health care100.00%
Quote time 2026-10-08 06:17:29 · For reference only, not investment advice and not tailored to your situation.